Renal artery stenosis-when to screen, what to stent?

Claudine G. Jennings (Lead / Corresponding author), John G. Houston, Alison Severn, Samira Bell, Isla S. Mackenzie, Thomas M. MacDonald

    Research output: Contribution to journalArticle

    15 Citations (Scopus)
    152 Downloads (Pure)

    Abstract

    Renal artery stensosis (RAS) continues to be a problem for clinicians, with no clear consensus on how to investigate and assess the clinical significance of stenotic lesions and manage the findings. RAS caused by fibromuscular dysplasia is probably commoner than previously appreciated, should be actively looked for in younger hypertensive patients and can be managed successfully with angioplasty. Atheromatous RAS is associated with increased incidence of cardiovascular events and increased cardiovascular mortality, and is likely to be seen with increasing frequency. Evidence from large clinical trials has led clinicians away from recommending interventional revascularisation towards aggressive medical management. There is now interest in looking more closely at patient selection for intervention, with focus on intervening only in patients with the highest-risk presentations such as flash pulmonary oedema, rapidly declining renal function and severe resistant hypertension. The potential benefits in terms of improving hard cardiovascular outcomes may outweigh the risks of intervention in this group, and further research is needed.
    Original languageEnglish
    Article number416
    Number of pages9
    JournalCurrent Atherosclerosis Reports
    Volume16
    Issue number6
    DOIs
    Publication statusPublished - Jun 2014

    Keywords

    • Atherosclerosis
    • Fibromuscular dysplasia
    • Percutaneous transluminal renal artery angioplasty
    • Renal artery stenosis

    Fingerprint Dive into the research topics of 'Renal artery stenosis-when to screen, what to stent?'. Together they form a unique fingerprint.

  • Cite this